Document Detail


Effects of chronic treatment with valproate and oxcarbazepine on testicular development in rats.
MedLine Citation:
PMID:  21169035     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The aim of this study was to examine the potential effects of valproate (VPA) and oxcarbazepine (OXC) on testicular development in rats.
METHODS: Forty-two Wistar rats were randomly divided into three groups of 14 rats each. Each group received the following via gavage over 90 days: group 1, tap water (control group); group 2, VPA (300mg/kg/day); group 3, OXC (100mg/kg/day). After sacrifice, body, testicular and epididymidis weights were measured. Testes were sampled, fixed and processed, and quantitative morphometric analysis of Sertoli cells, spermatocytes and spermatids was performed in stages II, V and XII by histopathological examination. Immunohistochemical staining was performed to transform growth factor beta 1 (TGF-β1) and p53, and the apoptotic index was assessed using the TUNEL method.
RESULTS: Testis and relative testis weights were significantly lower in the VPA group compared to the control group (p<0.05). Spermatogonia, pachytene spermatocyte and round spermatocyte numbers decreased in all stages in both the VPA and OXC groups compared to the control group, though this was not statistically significant (p>0.05). Apoptotic cell counts and p53 immunoreaction were significantly high and TGF-β1 expression was significantly lower in the VPA group compared to that of the control group (p<0.05). In the OXC group, p53 immunoreaction and TGF-β1 expression decreased compared to the control group, but this difference did not attain statistical significance (p>0.05).
CONCLUSIONS: Our results show that VPA treatment from prepuberty to adulthood significantly negatively affects spermatogenesis, not only by reducing testicular weight, but also by increasing apoptotic death and p53 and decreasing TGF-β1 activation. OXC has a minimal side effect on testicular development.
Authors:
Ali Cansu; Ozgür Ekinci; Ayse Serdaroglu; Seren Gulsen Gürgen; Ozalp Ekinci; Deniz Erdogan; Zafer Kutay Coskun; Lutfi Tunc
Related Documents :
21506955 - Changes in aldehyde dehydrogenase 2 expression in rat blood vessels during glyceryl tri...
21181115 - Anti-inflammatory effects of limb ischaemic preconditioning are mediated by sensory ner...
22918785 - Quercetin protects against chronic aluminum-induced oxidative stress and ensuing bioche...
21093615 - Carotid chemoafferent activity is not necessary for all phrenic long-term facilitation ...
3627075 - Influence of prenatal exposure to cimetidine and alcohol on selected morphological para...
8128495 - Cresol isomers: comparison of toxic potency in rat liver slices.
Publication Detail:
Type:  Journal Article     Date:  2010-12-18
Journal Detail:
Title:  Seizure     Volume:  20     ISSN:  1532-2688     ISO Abbreviation:  Seizure     Publication Date:  2011 Apr 
Date Detail:
Created Date:  2011-03-07     Completed Date:  2011-07-01     Revised Date:  2014-10-21    
Medline Journal Info:
Nlm Unique ID:  9306979     Medline TA:  Seizure     Country:  England    
Other Details:
Languages:  eng     Pagination:  203-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Animals, Newborn
Anticonvulsants / blood,  pharmacology*
Body Weight / drug effects
Carbamazepine / analogs & derivatives*,  blood,  pharmacology
Dose-Response Relationship, Drug
In Situ Nick-End Labeling / methods
Male
Organ Size / drug effects
Rats
Rats, Wistar
Sertoli Cells / drug effects
Spermatids / drug effects
Spermatocytes / drug effects
Testis / cytology,  drug effects*,  growth & development*
Transforming Growth Factor beta1 / metabolism
Tumor Suppressor Protein p53 / metabolism
Valproic Acid / blood,  pharmacology*
Chemical
Reg. No./Substance:
0/Anticonvulsants; 0/Transforming Growth Factor beta1; 0/Tumor Suppressor Protein p53; 33CM23913M/Carbamazepine; 614OI1Z5WI/Valproic Acid; VZI5B1W380/oxcarbazepine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Lymphoscintigraphic localization of a high-output chylus leak after bilateral lung transplantation.
Next Document:  Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 al...